Literature DB >> 23821585

Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.

Lambros Stamatakis1, M Minhaj Siddiqui, Jeffrey W Nix, Jennifer Logan, Soroush Rais-Bahrami, Annerleim Walton-Diaz, Anthony N Hoang, Srinivas Vourganti, Hong Truong, Brian Shuch, Howard L Parnes, Baris Turkbey, Peter L Choyke, Bradford J Wood, Richard M Simon, Peter A Pinto.   

Abstract

BACKGROUND: Active surveillance (AS) is an attempt to avoid overtreatment of clinically insignificant prostate cancer (PCa); however, patient selection remains controversial. Multiparametric prostate magnetic resonance imaging (MP-MRI) may help better select AS candidates.
METHODS: We reviewed a cohort of men who underwent MP-MRI with MRI/Ultrasound fusion-guided prostate biopsy and selected potential AS patients at entry using Johns Hopkins criteria. MP-MRI findings were assessed, including number of lesions, dominant lesion diameter, total lesion volume, prostate volume, and lesion density (calculated as total lesion volume/prostate volume). Lesions were assigned a suspicion score for cancer by MRI. AS criteria were reapplied based on the confirmatory biopsy, and accuracy of MP-MRI in predicting AS candidacy was assessed. Logistic regression modeling and chi-square statistics were used to assess associations between MP-MRI interpretation and biopsy results.
RESULTS: Eighty-five patients qualified for AS with a mean age of 60.2 years and mean prostate-specific antigen level of 4.8 ng/mL. Of these, 25 patients (29%) were reclassified as not meeting AS criteria based on confirmatory biopsy. Number of lesions, lesion density, and highest MRI lesion suspicion were significantly associated with confirmatory biopsy AS reclassification. These MRI-based factors were combined to create a nomogram that generates a probability for confirmed AS candidacy.
CONCLUSION: As clinicians counsel patients with PCa, MP-MRI may contribute to the decision-making process when considering AS. Three MRI-based factors (number of lesions, lesion suspicion, and lesion density) were associated with confirmatory biopsy outcome and reclassification. A nomogram using these factors has promising predictive accuracy for which future validation is necessary. Cancer 2013;119:3359-66. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  active surveillance; early detection of cancer; magnetic resonance imaging; prostate neoplasms

Mesh:

Year:  2013        PMID: 23821585      PMCID: PMC6663489          DOI: 10.1002/cncr.28216

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  85 in total

1.  Recent advances in surgical planning & navigation for tumor biopsy and resection.

Authors:  Defeng Wang; Diya Ma; Matthew Lun Wong; Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2015-10

2.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

3.  The role of image guided biopsy targeting in patients with atypical small acinar proliferation.

Authors:  Dima Raskolnikov; Soroush Rais-Bahrami; Arvin K George; Baris Turkbey; Nabeel A Shakir; Chinonyerem Okoro; Jason T Rothwax; Annerleim Walton-Diaz; M Minhaj Siddiqui; Daniel Su; Lambros Stamatakis; Pingkun Yan; Jochen Kruecker; Sheng Xu; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2014-08-20       Impact factor: 7.450

Review 4.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

5.  Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.

Authors:  Jonathan B Bloom; Graham R Hale; Samuel A Gold; Kareem N Rayn; Clayton Smith; Sherif Mehralivand; Marcin Czarniecki; Vladimir Valera; Bradford J Wood; Maria J Merino; Peter L Choyke; Howard L Parnes; Baris Turkbey; Peter A Pinto
Journal:  J Urol       Date:  2019-01       Impact factor: 7.450

Review 6.  Standards for prostate biopsy.

Authors:  Marc A Bjurlin; Samir S Taneja
Journal:  Curr Opin Urol       Date:  2014-03       Impact factor: 2.309

Review 7.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.

Authors:  Marc A Bjurlin; Xiaosong Meng; Julien Le Nobin; James S Wysock; Herbert Lepor; Andrew B Rosenkrantz; Samir S Taneja
Journal:  J Urol       Date:  2014-04-21       Impact factor: 7.450

8.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

9.  Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer.

Authors:  Soroush Rais-Bahrami; Baris Turkbey; Kinzya B Grant; Peter A Pinto; Peter L Choyke
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

10.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.